Economic analysis of higher-dose and standard-dose influenza vaccine for elderly
The analysis gathered data from a large-scale, multi-center efficacy trial. The trial evaluated a higher-dose split-virus inactivated influenza vaccine (IIV-HD) with a standard-dose split-virus inactivated influenza vaccine (IIV-SD) when they were administered to people 65 years old or older.
There were 31,989 adults involved in the trial. They were assigned to either IIV-HD (Sanofi Pasteur’s Fluzone High-Dose vaccine) or IIV-SD (Sanofi Pasteur’s Fluzone vaccine) with a 1:1 ratio. They were observed for six to eight months after receiving the vaccine. They were evaluated for medical encounters and adverse events.
The results were published in The New England Journal of Medicine. The IIV-HD group showed it was 24.2 percent more effective at preventing influenza-like, laboratory-confirmed illnesses compared to the group receiving IIV-SD. This amounts to a 97 percent confidence interval.
Dr. Ayman Chit, the senior director of Health Economics, Modeling and Market Access of North America with Sanofi Pasteur US, and his colleagues applied U.S. health care cost data to determine the economic impacts of the IIVS-HD as opposed to the IIV-SD for the trial participants.
Further details about the vaccines and the study are available online.